BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/23/2025 9:07:55 AM | Browse: 8 | Download: 37
 |
Received |
|
2025-02-08 06:17 |
|
Peer-Review Started |
|
2025-02-08 06:17 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-20 09:13 |
|
Revised |
|
2025-03-20 20:49 |
|
Second Decision |
|
2025-04-22 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-04-22 10:46 |
|
Articles in Press |
|
2025-04-22 10:46 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-04-29 03:00 |
|
Typeset the Manuscript |
|
2025-05-16 00:42 |
|
Publish the Manuscript Online |
|
2025-05-23 09:07 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Muhammad Abdul Rehman Gulzar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Abdul Rehman Gulzar, Bachelor of Medicine, Bachelor of Surgery, Multan Medical and Dental College, Multan Southern Bypass, Jahangirabad Shah Rukn E Alam Town, Multan 60000, Punjab, Pakistan. abdulrehman8104@gmail.com |
| Key Words |
Mineralocorticoid receptor antagonist; Finerenone; Semaglutide; Polypill framework; Antifibrotic; Glucagon-like peptide 1; Heart failure with preserved ejection fraction |
| Core Tip |
Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, it acts by reducing pathologic remodeling effects on heart and kidney while semaglutide improves glycemic control and improves lipid metabolism thereby regulating cardioprotective functions. Finerenone and semaglutide in combination reduces albuminuria, proinflammatory gene expression, preventing organ damage by mitigating fibrosis and inflammation, reducing obesity related cardiac remodeling and shown beneficial effects on heart failure with preserved ejection fraction by reducing preload and afterload thereby improves left ventricular function. |
| Publish Date |
2025-05-23 09:07 |
| Citation |
<p>Gulzar MAR. Finerenone and semaglutide: Role in heart failure with reduced ejection fraction. <i>World J Cardiol</i> 2025; 17(5): 105822</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i5/105822.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i5.105822 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
